4.7 Article

Elevated plasma neurofilament light predicts a faster rate of cognitive decline over 5 years in participants with objectively-defined subtle cognitive decline and MCI

Journal

ALZHEIMERS & DEMENTIA
Volume 17, Issue 10, Pages 1756-1762

Publisher

WILEY
DOI: 10.1002/alz.12324

Keywords

Alzheimer' s disease; early detection; mild cognitive impairment; neurofilament light; subtle cognitive decline

Funding

  1. U.S. Department of Veterans Affairs Clinical Sciences Research and Development Service (Merit Award) [1I01CX001842]
  2. U.S. Department of Veterans Affairs Clinical Sciences Research and Development Service ( Career Development Award-2) [1IK2CX001865, 1IK2CX001415]
  3. National Institute on Aging/National Institutes of Health (NIA/NIH) [R01 AG063782, R01 AG049810, R01 AG054049, R03 AG070435, P30 AG062429]
  4. Alzheimer's Association [AARF-17-528918, AARG-18-566254, AARG-17-500358]
  5. Alzheimer's Disease Neuroimaging Initiative (ADNI) (NIH) [U01 AG024904]
  6. DOD ADNI (Department of Defense) [W81XWH-12-2-0012]
  7. NIA, the National Institute of Biomedical Imaging and Bioengineering
  8. AbbVie
  9. Alzheimer's Association
  10. Alzheimer's DrugDiscovery Foundation
  11. Araclon Biotech
  12. BioClinica, Inc.
  13. Biogen
  14. Bristol-Myers Squibb Company
  15. CereSpir, Inc.
  16. Cogstate
  17. Eisai Inc.
  18. Elan Pharmaceuticals, Inc.
  19. Eli Lilly and Company
  20. EuroImmun
  21. F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.
  22. Fujirebio
  23. GE Healthcare
  24. IXICO Ltd.
  25. Janssen Alzheimer Immunotherapy Research & Development, LLC.
  26. Johnson & Johnson Pharmaceutical Research & Development LLC.
  27. Lumosity
  28. Lundbeck
  29. Merck Co., Inc.
  30. Meso Scale Diagnostics, LLC.
  31. NeuroRx Research
  32. Neurotrack Technologies
  33. Novartis Pharmaceuticals Corporation
  34. Pfizer Inc.
  35. Piramal Imaging
  36. Servier
  37. Takeda Pharmaceutical Company
  38. Transition Therapeutics
  39. Canadian Institutes of Health Research

Ask authors/readers for more resources

The study demonstrates the utility of plasma NFL as a biomarker of early AD-related changes, and supports the use of Obj-SCD criteria in clinical research to better capture subtle cognitive changes. Individuals with Obj-SCD and MCI showed elevated baseline plasma NFL relative to the cognitively normal group, and elevated NFL predicted faster rate of cognitive and functional decline across the sample. Within the Obj-SCD and MCI groups, higher NFL levels predicted faster rate of decline in memory and preclinical AD composite score compared to the cognitively normal group.
Introduction Neurofilament light (NFL) reflects neuroaxonal damage and is implicated in mild cognitive impairment (MCI) and Alzheimer's disease (AD). Little is known about NFL in pre-MCI stages, such as in individuals with objectively-defined subtle cognitive decline (Obj-SCD). Methods Two hundred ninety-four participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI) underwent baseline blood draw and serial neuropsychological testing over 5 years of follow-up. Results Individuals with Obj-SCD and MCI showed elevated baseline plasma NFL relative to the cognitively normal (CN) group. Across the sample, elevated NFL predicted faster rate of cognitive and functional decline. Within the Obj-SCD and MCI groups, higher NFL levels predicted faster rate of decline in memory and preclinical AD composite score compared to the CN group. Discussion Findings demonstrate the utility of plasma NFL as a biomarker of early AD-related changes, and provide support for the use of Obj-SCD criteria in clinical research to better capture subtle cognitive changes.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available